Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
出版年份 2021 全文链接
标题
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis
作者
关键词
-
出版物
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-07-02
DOI
10.1016/j.jaad.2021.06.869
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
- (2020) Pablo Olivera et al. GASTROENTEROLOGY
- Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis
- (2020) Karen M. Page et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Emerging systemic drugs in the treatment of plaque psoriasis
- (2020) Esther A. Balogh et al. EXPERT OPINION ON EMERGING DRUGS
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
- (2020) Brian S Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study
- (2020) Ravi Shankar P. Singh et al. CTS-Clinical and Translational Science
- Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists
- (2019) Tamara Pérez-Jeldres et al. Frontiers in Pharmacology
- JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
- (2019) Silvio Danese et al. GUT
- Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)
- (2019) Ryan Moslin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- (2019) Michael D. Howell et al. Frontiers in Immunology
- Systemic Treatment of Psoriasis with JAK Inhibitors: A Review
- (2019) Amanda Kvist-Hansen et al. Dermatology and Therapy
- Can IL-23 be a good target for ulcerative colitis?
- (2018) Mariangela Allocca et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Inhibition of interleukin-12 and/or interleukin-23 for the treatment of psoriasis: What is the evidence for an effect on malignancy?
- (2018) Elizabeth N. Ergen et al. EXPERIMENTAL DERMATOLOGY
- Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies
- (2018) Bani Ahluwalia et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)
- (2018) Andrew Fensome et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon-Inducible Myxovirus Resistance Proteins: Potential Biomarkers for Differentiating Viral from Bacterial Infections
- (2018) Vladimir P. Zav’yalov et al. CLINICAL CHEMISTRY
- IL-23 in inflammatory bowel diseases and colon cancer
- (2018) Markus F. Neurath CYTOKINE & GROWTH FACTOR REVIEWS
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Apremilast for the management of moderate to severe plaque psoriasis
- (2017) Ramya Vangipuram et al. Expert Review of Clinical Pharmacology
- Canonical and Non-Canonical Aspects of JAK–STAT Signaling: Lessons from Interferons for Cytokine Responses
- (2017) Andrea Majoros et al. Frontiers in Immunology
- Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
- (2017) Duk Hwan Kim et al. Immune Network
- Innate lymphoid cells in inflammatory bowel diseases
- (2016) C.P. Peters et al. IMMUNOLOGY LETTERS
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Psoriasis
- (2016) Jacqueline E. Greb et al. Nature Reviews Disease Primers
- Psoriasis: classical and emerging comorbidities
- (2015) Maria de Fátima Santos Paim de Oliveira et al. ANAIS BRASILEIROS DE DERMATOLOGIA
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Immunopathogenesis of IBD: current state of the art
- (2015) Heitor S. P. de Souza et al. Nature Reviews Gastroenterology & Hepatology
- Update on psoriasis immunopathogenesis and targeted immunotherapy
- (2015) Satveer K. Mahil et al. Seminars in Immunopathology
- Economic Burden of Psoriasis in the United States
- (2015) Elizabeth A. Brezinski et al. JAMA Dermatology
- Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
- (2014) Philip J. Mease et al. DRUGS
- Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells
- (2014) Hajime Akada et al. STEM CELLS
- Tyk2 is a therapeutic target for psoriasis-like skin inflammation
- (2013) M. Ishizaki et al. INTERNATIONAL IMMUNOLOGY
- A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
- (2013) S. J. Sohn et al. JOURNAL OF IMMUNOLOGY
- Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
- (2013) Sung O. Park et al. PLoS One
- Patients with Psoriasis Feel Stigmatized
- (2012) JC Szepietowski et al. ACTA DERMATO-VENEREOLOGICA
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011
- (2012) April W. Armstrong et al. PLoS One
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3: A two-faced player in hematological disorders
- (2009) Melanie G. Cornejo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leptin Stimulates Both JAK2-dependent and JAK2-independent Signaling Pathways
- (2008) Lin Jiang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started